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Letter to the Editor – Comments on published articles
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The ability of ANA antibodies to cause systemic lupus
1hepatitis  C,  interferón    y  lupus,  u
To the Editor,
Regarding the published article by Aun˜ón-Rubio et al.1 on
the development of systemic lupus erythematosus (SLE) in
patients with hepatitis C treated with alpha-interferon (IFN-),
I would like to add the issue of some patients with hepatitis C
being positive for antinuclear antibodies (ANA), and the pos-
sible liver damage of these antibodies.2 I would also like to
report the apparently innocuous development of these anti-
bodies after receiving IFN-,3 which occurred in one of our
patients.
This was a 51-year-old woman with chronic renal fail-
ure secondary to interstitial reﬂux nephropathy, on regular
haemodialysis since 1982, testing positive then for geno-
type 1b HCV. She received a renal transplant in 1988, and
re-started haemodialysis due to chronic graft nephropathy
in February 2007. In December 2007, after a normal auto-
immune study (including ANA), ultrasound, and Fibroscan®,
she received pegylated IFN monotherapy, with a sustained
virologic response and subsequent relapse. In January 2010,
she was successfully treated with IFN plus ribavirin, with riba-
virin level monitoring. At present, viral load has remained
negative, and hepatic Doppler ultrasound and Fibroscan® are
normal (4.8 kPa).
The following complications of antiviral treatment
occurred: depressive mood, leukopenia without need for IFN
adjustment, graft intolerance syndrome (GIS), and abnormal
erythrocyte morphology (dacrocytosis, anisocytosis). These
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all resolved after ﬁnishing treatment, without the need for
transplantectomy.
Regarding auto-immunity, at baseline, the patient was
negative for the various autoantibodies (ANA, ENA, AMA
[anti-mitochondrial], ASMA [anti-smooth muscle], APCA [anti-
parietal cell] and LKM1 [liver kidney anti-microsomal type 1]),
and complement was normal (C3, C4). From the sixth month
post-treatment, she began to test positive for ANA, reaching
a titre of up to 1:640 on IFL, and then became negative before
the ﬁrst IFN withdrawal. She again tested positive for ANA,
after the second IFN treatment, and has remained positive
after withdrawal of the drug until present. Anti-DNA and anti-
ENA antibodies and complement have always been within the
normal range. She has not had any symptoms suggestive of
lupus.
“Native” and post-IFN-therapy positivity for ANA autoanti-
bodies are known to occur in patients with hepatitis C,2–6 being
present in up to one third of cases, although the homogeneous
pattern is less common.2 Other autoantibodies have also been
detected in this population (SMA, anti-LKM 1), though less fre-
quently. Therefore, even with a high suspicion of viral liver
disease, the protocol is to determine the auto-antibody proﬁle
in these patients, due to the co-existence of viral hepatitis and
auto-immune hepatitis (AIH), particularly if the patient is to
receive antiviral therapy. C. Comentario a «Infección por virus de la hepatitis C, interferón
erythematosus has been studied, as has their possible rela-
tionship to the severity and clinical course of liver disease,2,4,5
1 5;3  5
t
o
p
a
r
H
t
p
i
a
A
o
s
j
c
t
S
r
1
2
3
4
5
6
L ish
R on
i  a
R ció
i so
D
W
c
A
a
H
a
m
h
un e f r o l o g i a. 2 0 
hough the different ways in which one condition causes the
ther are not known. Some studies have suggested that in
atients with chronic HCV+ hepatitis, the whole panel of auto-
ntibodies (AMA, ANA, anti-SMA, anti-LKM) could affect the
esponse to interferon and clinical proﬁle of liver disease.6
owever, when ANA was analysed separately, it did not appear
o conﬁrm these assumptions.5 Fortunately, it seems that the
resence of these ANAs in HCV+ patients with or without IFN
s not related to IFN efﬁcacy.3
Our patient became positive only for ANA, remaining neg-
tive for the rest of the antibodies related to both lupus and
IH. She has not developed either of these clinical syndromes
r classical viral relapse (occult HCV not analysed). Although
he has not had a liver biopsy at any time, currently, we  see no
ustiﬁcation for monitoring these antibodies unless she shows
linical or biochemical abnormalities of some form.
In patients with hepatitis C, with or without interferon
reatment, ANA not only bears the possibility of developing
LE, but could also be related with the hepatic infection itself.
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As she clearly explains in her remark, the presence of
ntinuclear antibodies (ANA) among patients with chronic
CV infection has been extensively described in the literature
s an immune epiphenomenon lacking clinical signiﬁcance in
ost cases.2
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Additional supporting tests, including extending the
autoantibody proﬁle, should only be performed in patients
whose clinical or analytical ﬁndings are unrelated to hepati-
tis C. This rules out associated diseases, such as autoimmune
hepatitis or drug-induced lupus.
Following treatment, our patient had fever, asthenia, and
arthralgia, as well as positive anti-histone antibodies. Therio de «Infección por virus de la hepatitis C, interferón  y lupus,
temporal relationship between concomitant interferon treat-
ment and negative HCV tests resulted in the diagnosis and
subsequent therapy of the patient.
